• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

土耳其发表文献的荟萃分析:莱顿因子 V 在成年静脉血栓栓塞症患者中的作用

The role of Factor V Leiden in adult patients with venous thromboembolism: a meta-analysis of published studies from Turkey.

机构信息

General Surgery, Ankara University Medical School, Ankara, Turkey.

出版信息

Clin Appl Thromb Hemost. 2012 Jan-Feb;18(1):40-4. doi: 10.1177/1076029611412369. Epub 2011 Jul 6.

DOI:10.1177/1076029611412369
PMID:21733936
Abstract

Factor V Leiden (FVL) is the most common inherited risk factor for venous thromboembolism (VTE). The frequency of FVL in patients with VTE has been reported from different parts of Turkey. A meta-analysis was performed to estimate the risk of VTE associated with FVL in Turkish population. Published studies were retrieved from Pubmed and Science Citation Index/Expanded. We selected studies comparing the prevalence of FVL in patients with VTE with controls. The analysis was performed by the software comprehensive meta-analysis. The analysis consisted of 10 studies including 1202 patients with VTE and 1283 controls. The pooled frequency of FVL was significantly higher in patients with VTE (22.8%) than controls (7.6%). The pooled odds ratio (OR) was 3.4 (95% confidence interval [CI], 2.6-4.5). The study showed homogeneity (Q value, 9.955). No publication bias was observed in any comparison model. Our meta-analysis showed an association of FVL with VTE in Turkey.

摘要

因子 V 莱顿(FVL)是静脉血栓栓塞症(VTE)最常见的遗传性危险因素。FVL 在土耳其不同地区 VTE 患者中的频率已有报道。进行了一项荟萃分析,以评估 FVL 与土耳其人群 VTE 相关的风险。从 Pubmed 和科学引文索引/扩展版检索已发表的研究。我们选择了比较 VTE 患者和对照组中 FVL 患病率的研究。使用综合荟萃分析软件进行分析。该分析包括 10 项研究,共纳入 1202 例 VTE 患者和 1283 例对照组。VTE 患者中 FVL 的总频率明显高于对照组(22.8% vs. 7.6%)。合并优势比(OR)为 3.4(95%置信区间[CI],2.6-4.5)。该研究显示具有同质性(Q 值为 9.955)。在任何比较模型中均未观察到发表偏倚。我们的荟萃分析显示 FVL 与土耳其的 VTE 之间存在关联。

相似文献

1
The role of Factor V Leiden in adult patients with venous thromboembolism: a meta-analysis of published studies from Turkey.土耳其发表文献的荟萃分析:莱顿因子 V 在成年静脉血栓栓塞症患者中的作用
Clin Appl Thromb Hemost. 2012 Jan-Feb;18(1):40-4. doi: 10.1177/1076029611412369. Epub 2011 Jul 6.
2
Factor V 1691 G-A (Leiden) polymorphism and cancer-related venous thromboembolism: a meta-analysis of published studies.凝血因子V 1691 G-A(莱顿)基因多态性与癌症相关的静脉血栓栓塞:已发表研究的荟萃分析
J BUON. 2008 Jan-Mar;13(1):61-4.
3
High frequency of factor V Leiden in surgical patients with symptomatic venous thromboembolism despite prophylaxis.尽管采取了预防措施,但有症状静脉血栓栓塞的外科手术患者中因子V莱顿突变的高发生率。
Thromb Haemost. 2007 Feb;97(2):171-5.
4
[The Bavarian Thromboembolic Risk Cohort Study (BATER). Study protocol, state of the investigation and first results].[巴伐利亚血栓栓塞风险队列研究(BATER)。研究方案、调查现状及初步结果]
Dtsch Med Wochenschr. 2000 Jan 7;125(1-2):2-6. doi: 10.1055/s-2007-1023875.
5
Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives?对凝血因子V莱顿突变进行选择性筛查:在开具口服避孕药之前这样做是否可取?
Thromb Haemost. 1997 Dec;78(6):1480-3.
6
Factor V Leiden and prothrombin gene G20210A mutation in children with venous thromboembolism.儿童静脉血栓栓塞症中的凝血因子V莱顿突变和凝血酶原基因G20210A突变
Thromb Haemost. 2002 Jun;87(6):972-7.
7
Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism.凝血因子V莱顿突变与凝血酶原20210A联合作用对静脉血栓栓塞风险的影响——对8项病例对照研究的汇总分析,包括2310例病例和3204例对照。静脉血栓栓塞汇总分析研究组
Thromb Haemost. 2001 Sep;86(3):809-16.
8
Incidence of venous thromboembolism in first-degree relatives of patients with venous thromboembolism who have factor V Leiden.患有因子V莱顿突变的静脉血栓栓塞症患者一级亲属的静脉血栓栓塞发病率。
Thromb Haemost. 2006 Dec;96(6):744-9.
9
Venous thrombotic risk in family members of unselected individuals with factor V Leiden.携带凝血因子V莱顿突变的非选择性个体家庭成员的静脉血栓形成风险
Thromb Haemost. 2000 Jun;83(6):817-21.
10
Prevalence and association of the factor V Leiden and prothrombin G20210A in healthy subjects and patients with venous thromboembolism.健康受试者及静脉血栓栓塞症患者中凝血因子V莱顿突变和凝血酶原G20210A突变的患病率及相关性
Croat Med J. 2001 Aug;42(4):488-92.

引用本文的文献

1
The prevalence of Factor V Leiden, prothrombin G20210A, MTHFR C677T and MTHFR A1298C mutations in healthy Turkish population.健康土耳其人群中凝血因子V莱顿突变、凝血酶原G20210A突变、亚甲基四氢叶酸还原酶C677T突变和亚甲基四氢叶酸还原酶A1298C突变的患病率。
Hippokratia. 2015 Oct-Dec;19(4):309-13.
2
Factor V Leiden and Prothrombin 20210A Mutations among Turkish Pediatric Leukemia Patients.土耳其儿童白血病患者中的凝血因子V莱顿突变和凝血酶原20210A突变
Leuk Res Treatment. 2012;2012:250432. doi: 10.1155/2012/250432. Epub 2012 Feb 16.
3
The distribution of Factor V Leiden mutation.
凝血因子V莱顿突变的分布情况。
J Thromb Thrombolysis. 2013 Oct;36(3):341-2. doi: 10.1007/s11239-012-0848-x.